Results 71 to 80 of about 75,344 (257)

Preoperative detection of functional somatostatin receptors in a patient with an insulinoma

open access: yesClinical Case Reports, 2023
Key Clinical Message Octreotide is used in patients with insulinomas to treat hypoglycemia, and somatostatin receptor (SSTR) 2 expression is important for its efficacy. We report a case of insulinoma in a 50‐year‐old woman that responded to an octreotide
Kohei Oguni   +6 more
doaj   +1 more source

Evaluation of radiological and clinical efficacy of ^{90}Y-DOTATATE} therapy in patients with progressive metastatic midgut neuroendocrine carcinomas [PDF]

open access: yes, 2009
Background: To evaluate the radiological and clinical therapeutic effectiveness of ^{90}Y-octreotate [DOTATATE] inpatients with progressive somatostatin receptor-positive midgut neuroendocrine carcinomas (GEPNETs).
Buscombe, John R.   +7 more
core  

Targeted radiotherapy of neuroblastoma: future directions [PDF]

open access: yes, 2017
No abstract ...
Gaze, Mark N.   +4 more
core   +2 more sources

Duodenal carcinoid tumour – a case report [PDF]

open access: yes, 2020
Duodenal carcinoids are rare tumours of the small intestine with heterogenous clinical and pathological characteristics. The long-term prognosis is very good if discovered in the early stages.
Alexescu, Teodora Gabriela   +7 more
core   +2 more sources

Pituitary somatostatin receptor signaling [PDF]

open access: yesTrends in Endocrinology & Metabolism, 2010
Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor subtypes (SSTR1-5) are ubiquitously expressed G-protein coupled receptors.
Anat, Ben-Shlomo, Shlomo, Melmed
openaire   +2 more sources

Photocaged Oxytocin and Vasopressin Probes to Decipher Neuropeptide Signalling With High Spatiotemporal Resolution

open access: yesAngewandte Chemie International Edition, EarlyView.
Novel and biocompatible photoactivatable oxytocin and vasopressin probes, utilising state‐of‐the‐art photocages, remain inactive in the dark. Light exposure facilitates rapid spatiotemporal receptor activation and phospholipase C (PLC)‐mediated downstream signalling. Figure created in https://BioRender.com.
Konstantin Raabe   +7 more
wiley   +1 more source

Acromegaly: pathogenesis & treatment [PDF]

open access: yes, 2019
Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

open access: yesClinics
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades.
Maria de Fátima Borges   +8 more
doaj   +1 more source

Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.

open access: yesPLoS ONE, 2017
Cancer stem cells represent the putative tumor-driving subpopulation thought to account for drug resistance, relapse, and metastatic spread of epithelial and other cancer types.
Sif Holmboe   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy